[go: up one dir, main page]

CR20170563A - Compuestos de benzoxacepina oxazolidinona y métodos de uso. - Google Patents

Compuestos de benzoxacepina oxazolidinona y métodos de uso.

Info

Publication number
CR20170563A
CR20170563A CR20170563A CR20170563A CR20170563A CR 20170563 A CR20170563 A CR 20170563A CR 20170563 A CR20170563 A CR 20170563A CR 20170563 A CR20170563 A CR 20170563A CR 20170563 A CR20170563 A CR 20170563A
Authority
CR
Costa Rica
Prior art keywords
benzoxacepin
methods
pi3k
oxazolidinone compounds
compounds
Prior art date
Application number
CR20170563A
Other languages
English (en)
Inventor
Richard; Elliott
Emily Hanan
Robert Andrew; Heald
Marie-Gabrielle Braun
Calum; Macleod
Steven T ; Staben
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20170563A publication Critical patent/CR20170563A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describen compuestos de benzoxacepina oxazolidinona con actividad o función moduladora de fosfoinosítido 3 cinasa (PI3K) que tienen la estructura de fórmula I: I o estereoisómeros, tautómeros, o sales farmacéuticamente aceptable de los mismos, y con los sustituyentes y características estructurales descritas en el presente documento. También se describen composiciones farmacéuticas y medicamentos que incluyen los compuestos de fórmula I, así como métodos para usar dichos moduladores de PI3K, solos o en combinación con otros agentes terapéuticos, para tratar enfermedades o afecciones que están mediadas o que son dependientes de la desregulación de PI3K.
CR20170563A 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y métodos de uso. CR20170563A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188029P 2015-07-02 2015-07-02
PCT/EP2016/065455 WO2017001645A1 (en) 2015-07-02 2016-07-01 Benzoxazepin oxazolidinone compounds and methods of use

Publications (1)

Publication Number Publication Date
CR20170563A true CR20170563A (es) 2018-02-20

Family

ID=56292756

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170563A CR20170563A (es) 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y métodos de uso.

Country Status (33)

Country Link
US (7) US9650393B2 (es)
EP (5) EP3567045B1 (es)
JP (4) JP6523490B2 (es)
KR (2) KR102014326B1 (es)
CN (4) CN112062778B (es)
AR (1) AR105238A1 (es)
AU (2) AU2016287463B2 (es)
CA (1) CA2982708C (es)
CL (1) CL2017003436A1 (es)
CO (1) CO2017011038A2 (es)
CR (1) CR20170563A (es)
DK (1) DK3317284T3 (es)
ES (2) ES2764497T3 (es)
FI (1) FIC20253008I1 (es)
HR (1) HRP20192349T1 (es)
HU (1) HUE046756T2 (es)
IL (3) IL255200B (es)
LT (2) LT3317284T (es)
MA (3) MA42295B1 (es)
MX (2) MX372624B (es)
MY (1) MY195002A (es)
PE (2) PE20211775A1 (es)
PH (2) PH12017502425A1 (es)
PL (2) PL3567045T3 (es)
PT (1) PT3317284T (es)
RS (1) RS59740B1 (es)
RU (1) RU2730529C2 (es)
SG (1) SG10201913980SA (es)
SI (1) SI3317284T1 (es)
TW (4) TWI601732B (es)
UA (1) UA121678C2 (es)
WO (1) WO2017001645A1 (es)
ZA (1) ZA201808370B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2764497T3 (es) 2015-07-02 2020-06-03 Hoffmann La Roche Compuestos de benzoxazepina oxazolidinona y procedimientos de uso
TWI788830B (zh) 2015-07-02 2023-01-01 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
CN108349996B (zh) 2015-09-08 2021-01-08 豪夫迈·罗氏有限公司 三环pi3k抑制剂化合物及其使用方法
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018073193A1 (en) 2016-10-17 2018-04-26 F. Hoffmann-La Roche Ag Bicyclic pyridone lactams and methods of use thereof
KR102537048B1 (ko) * 2016-12-15 2023-05-26 에프. 호프만-라 로슈 아게 (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노) 프로판아미드의 제조 방법
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
EP3615541B1 (en) * 2017-04-28 2025-03-19 F. Hoffmann-La Roche AG Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
CN112074519B (zh) 2018-04-20 2024-08-02 豪夫迈·罗氏有限公司 作为rip1激酶抑制剂用于治疗例如肠易激综合征(ibs)的化合物
EP3805231B1 (en) * 2018-05-30 2024-10-16 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
JP2021532139A (ja) * 2018-07-23 2021-11-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｉ３ｋ阻害剤であるｇｄｃ−００７７による癌の治療方法
CN112839642A (zh) 2018-10-08 2021-05-25 豪夫迈·罗氏有限公司 用PI3Kα抑制剂和二甲双胍治疗癌症的方法
CN109265408B (zh) * 2018-12-11 2020-09-01 上海皓元生物医药科技有限公司 二氟甲基取代噁烷-2-酮的合成方法
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
CN111995541B (zh) * 2019-05-27 2025-05-06 君实润佳(上海)医药科技有限公司 含有稳定重同位素的酰胺官能团的化合物及其应用
JP7656589B2 (ja) 2019-08-26 2025-04-03 アルビナス・オペレーションズ・インコーポレイテッド エストロゲン受容体分解物質としてのテトラヒドロナフタレン誘導体を用いて乳癌を治療する方法
WO2021088845A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
KR20220119610A (ko) * 2019-11-25 2022-08-30 상하이 한서 바이오메디컬 컴퍼니 리미티드 3개의 융합된 고리 유도체-함유 염 또는 결정 형태 및 이의 약학 조성물
TW202133857A (zh) * 2019-12-03 2021-09-16 美商建南德克公司 用於乳癌治療之組合療法
JP2024501445A (ja) 2020-12-11 2024-01-12 ジェネンテック， インコーポレイテッド Ｈｅｒ２がんの処置のための併用療法
CA3206323A1 (en) * 2021-01-29 2022-08-04 Jingjie HUANG Tricyclic compounds and use thereof
JP2024520920A (ja) 2021-05-13 2024-05-27 貝達薬業股▲ふん▼有限公司 イミダゾリジノン類化合物の多形体、調製方法及びその使用
WO2022251567A1 (en) 2021-05-28 2022-12-01 Genentech, Inc. Process for the preparation of benzoxazepin oxazolidinone compounds
JP7537026B2 (ja) 2021-07-19 2024-08-20 京セラ株式会社 通信方法、ユーザ装置、ネットワーク装置、移動通信システム、プログラム及びチップセット
PE20240652A1 (es) * 2021-08-09 2024-04-04 Scorpion Therapeutics Inc Compuestos que inhiben la isoforma alfa de pi3k y metodos para tratar el cancer
IL315250A (en) 2022-04-06 2024-10-01 Genentech Inc Combination therapies including GDC-6036 and GDC-0077 for the treatment of cancer
WO2024022435A1 (zh) * 2022-07-27 2024-02-01 南京明德新药研发有限公司 一种5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英化合物的晶型及其制备方法
EP4615431A1 (en) 2022-11-11 2025-09-17 Astrazeneca AB Combination therapies for the treatment of cancer
WO2024206147A1 (en) 2023-03-24 2024-10-03 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
WO2025036856A1 (en) 2023-08-11 2025-02-20 F. Hoffmann-La Roche Ag Pharmaceutical formulation comprising a coated tablet
US20250177414A1 (en) 2023-12-04 2025-06-05 Genentech, Inc. Combination therapies for treatment of breast cancer
WO2025122745A1 (en) 2023-12-05 2025-06-12 Genentech, Inc. Combination therapies for treatment of her2 cancer
WO2025181153A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JP4642309B2 (ja) 2000-04-25 2011-03-02 イコス・コーポレイション ヒトホスファチジル−イノシトール３−キナーゼデルタの阻害剤
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP2088147A1 (en) * 2003-12-22 2009-08-12 Arcadia Pharmaceuticals Inc. Dibenzo-condensed azepine, diazepine, oxazepine and thiazepine derivatives as muscarinic agonists and methods of treatment of neuropsychiatric disorders
ES2873875T3 (es) 2004-05-13 2021-11-04 Icos Corp Quinazolinonas como inhibidores de fosfatidilinositol 3-quinasa delta humano
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
EA200702235A1 (ru) 2005-05-04 2008-04-28 Пфайзер Лимитед Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
DK1934174T3 (da) 2005-10-07 2011-08-01 Exelixis Inc Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
PT2024372E (pt) 2006-04-26 2010-09-16 Hoffmann La Roche Derivado de tieno[3,2-d]pirimidina útil como inibidor de pi3k
GB0610866D0 (en) 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
EP2201840B1 (en) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
CL2007003520A1 (es) 2006-12-07 2008-08-22 Piramed Ltd Genentech Inc Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
KR20100090289A (ko) * 2007-11-21 2010-08-13 디코드 제네틱스 이에이치에프 염증, 심혈관 및 중추신경계 질환의 치료를 위한 치환된 벤조아졸 ｐｄｅ4 억제제
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
KR20140034948A (ko) 2009-09-28 2014-03-20 에프. 호프만-라 로슈 아게 벤즈옥세핀 ｐｉ3ｋ 억제제 화합물 및 사용 방법
US8242104B2 (en) 2009-09-28 2012-08-14 F. Hoffman-La Roche Ag Benzoxazepin P13K inhibitor compounds and methods of use
US20120231015A1 (en) * 2009-11-06 2012-09-13 Emory University Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
EP2688891B1 (en) 2011-03-21 2017-11-15 F. Hoffmann-La Roche AG Benzoxazepin compounds selective for pi3k p110 delta and methods of use
PH12013502697A1 (en) 2011-07-01 2014-02-10 Novartis Ag Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34632A (es) * 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
WO2013134288A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
JP6121520B2 (ja) * 2012-03-30 2017-04-26 ブリガム・ヤング・ユニバーシティＢｒｉｇｈａｍ Ｙｏｕｎｇ Ｕｎｉｖｅｒｓｉｔｙ 摩擦攪拌作業のプロセス制御のための作用力調節
KR101689946B1 (ko) 2012-06-08 2016-12-26 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
KR20180070715A (ko) * 2013-03-13 2018-06-26 에프. 호프만-라 로슈 아게 벤즈옥사제핀 화합물의 제조 방법
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
CN111848643A (zh) 2015-07-02 2020-10-30 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
ES2764497T3 (es) 2015-07-02 2020-06-03 Hoffmann La Roche Compuestos de benzoxazepina oxazolidinona y procedimientos de uso
KR102537048B1 (ko) 2016-12-15 2023-05-26 에프. 호프만-라 로슈 아게 (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노) 프로판아미드의 제조 방법
EP3615541B1 (en) * 2017-04-28 2025-03-19 F. Hoffmann-La Roche AG Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
JP2021532139A (ja) 2018-07-23 2021-11-25 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｉ３ｋ阻害剤であるｇｄｃ−００７７による癌の治療方法
CN112839642A (zh) 2018-10-08 2021-05-25 豪夫迈·罗氏有限公司 用PI3Kα抑制剂和二甲双胍治疗癌症的方法
TW202133857A (zh) 2019-12-03 2021-09-16 美商建南德克公司 用於乳癌治療之組合療法

Also Published As

Publication number Publication date
CO2017011038A2 (es) 2018-02-09
JP2023103242A (ja) 2023-07-26
HK1253003A1 (zh) 2019-06-06
JP6880101B2 (ja) 2021-06-02
US11760753B2 (en) 2023-09-19
EP4212536A1 (en) 2023-07-19
PH12020551315A1 (en) 2021-07-05
PE20211775A1 (es) 2021-09-08
TW202108592A (zh) 2021-03-01
US20210246129A1 (en) 2021-08-12
HRP20192349T1 (hr) 2020-03-20
MY195002A (en) 2022-12-30
AU2020204418A1 (en) 2020-07-23
PH12017502425A1 (en) 2018-07-02
IL255200B (en) 2020-05-31
JP2021119144A (ja) 2021-08-12
NZ736222A (en) 2024-05-31
RU2018103454A (ru) 2019-08-05
US20170015678A1 (en) 2017-01-19
MA54252A (fr) 2022-04-27
ZA201808370B (en) 2023-03-29
TWI649326B (zh) 2019-02-01
IL272277A (en) 2020-02-27
FIC20253008I1 (fi) 2025-09-22
UA121678C2 (uk) 2020-07-10
MX2017016344A (es) 2018-05-02
TWI698440B (zh) 2020-07-11
US10112932B2 (en) 2018-10-30
CN112047960B (zh) 2024-08-02
MA49861A (fr) 2021-05-05
EP3317284A1 (en) 2018-05-09
EP3317284B1 (en) 2019-10-30
KR20180006460A (ko) 2018-01-17
TW201936612A (zh) 2019-09-16
TWI601732B (zh) 2017-10-11
RS59740B1 (sr) 2020-02-28
PL3317284T3 (pl) 2020-04-30
PL3567045T3 (pl) 2022-04-19
KR20190100432A (ko) 2019-08-28
US20250197386A1 (en) 2025-06-19
EP4212536B1 (en) 2025-02-19
SI3317284T1 (sl) 2020-02-28
RU2730529C2 (ru) 2020-08-24
LT3317284T (lt) 2020-01-27
MA42295B1 (fr) 2020-02-28
JP7266630B2 (ja) 2023-04-28
CN111909173A (zh) 2020-11-10
JP2019178135A (ja) 2019-10-17
IL272277B (en) 2021-01-31
TW201815798A (zh) 2018-05-01
BR112017023121A2 (pt) 2018-07-10
CL2017003436A1 (es) 2018-05-04
AU2016287463A1 (en) 2017-10-26
WO2017001645A1 (en) 2017-01-05
ES2764497T3 (es) 2020-06-03
KR102306071B1 (ko) 2021-10-01
US20190263793A1 (en) 2019-08-29
LTPA2025536I1 (es) 2025-10-10
RU2018103454A3 (es) 2019-11-21
DK3317284T3 (da) 2020-01-13
IL255200A0 (en) 2017-12-31
EP4585597A1 (en) 2025-07-16
AR105238A1 (es) 2017-09-20
CN112062778B (zh) 2024-04-19
EP3567045B1 (en) 2022-01-12
IL277774A (en) 2020-11-30
US20170210733A1 (en) 2017-07-27
NZ775526A (en) 2024-05-31
CN107873032B (zh) 2020-07-17
EP3567045A1 (en) 2019-11-13
US9650393B2 (en) 2017-05-16
US20240199594A1 (en) 2024-06-20
EP3778607C0 (en) 2023-08-30
HUE046756T2 (hu) 2020-03-30
TW201712020A (zh) 2017-04-01
MX372624B (es) 2020-05-07
PE20181021A1 (es) 2018-06-27
MX388533B (es) 2025-03-20
US20180127404A1 (en) 2018-05-10
EP3778607B1 (en) 2023-08-30
AU2020204418B2 (en) 2022-02-03
PT3317284T (pt) 2020-01-10
CA2982708C (en) 2023-10-03
ES2908300T3 (es) 2022-04-28
JP6523490B2 (ja) 2019-06-05
CA2982708A1 (en) 2017-01-05
CN112062778A (zh) 2020-12-11
CN107873032A (zh) 2018-04-03
CN111909173B (zh) 2025-03-04
EP3778607A1 (en) 2021-02-17
SG10201913980SA (en) 2020-03-30
KR102014326B1 (ko) 2019-08-26
CN112047960A (zh) 2020-12-08
MX2020003415A (es) 2021-12-07
US10851091B2 (en) 2020-12-01
AU2016287463B2 (en) 2020-07-02
EP4212536C0 (en) 2025-02-19
JP2018519307A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
MX2020003532A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrogenos y usos de los mismos.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
CO2019009722A2 (es) Dendrímeros terapéuticos
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
PE20151607A1 (es) Formulaciones de compuestos organicos
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY36608A (es) Derivados de indol
AR122456A2 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos